EU Approval for Vision-Restoring Chip Opens New Investment Frontier in Medical Tech

Science Corporation, the neurotechnology firm led by former Neuralink president Max Hodak, has secured European Union approval for its vision-restoring chip. The device, designed to restore sight in patients with certain forms of blindness, now enters a market that Hodak argues is still searching for a revenue anchor. In a statement accompanying the regulatory green light, Hodak asserted that the field requires at least one company generating $100 million in yearly revenue to prove the business model works.

The EU approval positions Science Corporation to begin commercialization in a bloc with a large and aging population, where age-related vision loss is a growing concern. The company's chip is a retinal implant that bypasses damaged photoreceptors, directly stimulating the remaining retinal cells to create visual perception. This technology sits at the intersection of biotech, semiconductor engineering, and artificial intelligence, making it a multi-sector play.

From a business perspective, the announcement is significant because it moves the company from R&D into revenue generation. Hodak's comment about the $100 million revenue target suggests Science Corporation is aiming to be the first player in the space to achieve meaningful scale. That target could attract growth-stage investors looking for a bet with a clear path to commercial traction, especially as the global market for visual prosthetics is projected to expand rapidly over the next decade.

The regulatory milestone also creates ripple effects for suppliers and partners in the semiconductor supply chain, custom chip manufacturing, and medical device contract manufacturing. While Science Corporation itself is not publicly traded, its success could lift the entire neurotech sector, potentially influencing valuations of related private companies or public firms with adjacent technologies, such as cochlear implant makers or retinal surgery equipment manufacturers.

For investors, the key takeaway is that the EU approval validates the technical and regulatory feasibility of brain-computer interfaces for medical use. The broader sector now has a precedent for gaining regulatory approval, which could accelerate timelines for competitors and open up new funding rounds. Hodak's revenue target underscores that the focus is shifting from science fiction to scalable business models.

The practical impact extends to patients and healthcare systems as well. If Science Corporation succeeds in capturing a meaningful share of the European market, it could drive down costs for vision restoration procedures over time, creating opportunities for healthcare providers to offer new services and for insurers to develop specialized coverage products.